EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort

Alica Kubesch, Nina Kruse, Florian Jungheim, Ümniye Balaban, Katharina Stratmann, Kathrin Sprinzl, Antje Dienethal, Thomas Krause, Stefan Zeuzem, Irina Blumenstein

Journal of Clinical Medicine · 13.12.2023 · 12 (24) · 7657

DOI: 10.3390/jcm12247657 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.12.2023. Verfasst von Alica Kubesch und 9 weiteren Autor:innen. Beteiligte Einrichtung: Goethe University Frankfurt, University Hospital, Medical Clinic 1, 60596 Frankfurt a.M., Germany. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: INITIALISE-ACS Program Frankfurt.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vedolizumab (VDZ) for subcutaneous (SC) injection was approved for use in Europe in 2020 and the US in 2023. Promising efficacy and tolerability have been proven in pivotal trials. However, real-world data on the SC use of VDZ, especially in patients with active disease, are still lacking. We aimed to determine treatment persistence and the drug’s efficacy in inflammatory bowel disease (IBD) patients with active disease in comparison to patients in clinical remission.

Methods

Patients treated for IBD in a tertiary care center from July 2020 to December 2021 were included in this study. Clinical and biochemical parameters and data on treatment adherence were collected. VDZ trough levels and disease activity before and after the switch from intravenous (IV) to SC injections were monitored during routine checkups and were retrospectively analyzed. The patients were followed up until week 20.

Results

Eighty-two patients were included in the study. Of them, 35 patients had active disease (35/82 = 43%) at the time of the switch and 47 patients (47/82 = 57%) were in remission. In total, 10 patients experienced switch failure, 5 were switched back to IV VDZ, and 5 were swapped to a different biologic agent. We observed an increase in VDZ trough levels from the switch to week 8 and from the switch to week 20 in the remission group. Vedolizumab trough levels of 7.4, 51.4, and 33.45 ug/mL at the switch, week 8, and week 20 were identified to discriminate between remission and disease activity in our cohort. There was no new safety signal detected during the study period.

Conclusions

The switch from IV to SC VDZ proved to be efficient, safe, and even capable of reducing residual disease activity.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseaseIBDbiologicsreal-world datasub-cutaneous applicationtrough levelsulcerative colitisvedolizumab

Autor:innen und Institutionen

  • Goethe University Frankfurt, University Hospital, Medical Clinic 1, 60596 Frankfurt a.M., Germany.
  • Institute of Biostatistics and Mathematical Modeling, University Hospital, Goethe University, 60596 Frankfurt a.M., Germany.
  • Gastroenterologie Opernstrasse, 34117 Kassel, Germany.

Förderung

  • INITIALISE-ACS Program Frankfurt

Zitieren

APA

Kubesch, A., Kruse, N., Jungheim, F., Balaban, Ü., Stratmann, K., Sprinzl, K., Dienethal, A., Krause, T., Zeuzem, S., & Blumenstein, I. (2023). Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort. Journal of Clinical Medicine, 12(24), 7657. https://doi.org/10.3390/jcm12247657

Vancouver

Kubesch A, Kruse N, Jungheim F, Balaban Ü, Stratmann K, Sprinzl K, et al. Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort. Journal of Clinical Medicine. 2023;12(24):7657. doi:10.3390/jcm12247657

BibTeX
@article{Kubesch2023,
  author = {Kubesch, Alica and Kruse, Nina and Jungheim, Florian and Balaban, Ümniye and Stratmann, Katharina and Sprinzl, Kathrin and Dienethal, Antje and Krause, Thomas and Zeuzem, Stefan and Blumenstein, Irina},
  title = {Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {24},
  pages = {7657},
  doi = {10.3390/jcm12247657}
}
Kostenlos starten →